Pharmaceutical Patent Analyst

metrics 2024

Unveiling Strategies for Pharmaceutical Innovation and Compliance

Introduction

Pharmaceutical Patent Analyst, published by Taylor & Francis Ltd, is a premier journal dedicated to the evolving fields of pharmaceutical science and patent law. Established in 2012, this journal provides a rigorous platform for scholarly articles, analytical studies, and insightful reviews that delve into the intersection of drug discovery, pharmaceutical innovation, and intellectual property rights. With a Q2 category ranking in Pharmaceutical Science and Q3 rankings in both Drug Discovery and Medicine (miscellaneous), it is recognized for its impactful contributions to the academic community and industry professionals alike. The journal aims to enhance the understanding of patent strategies, explore emerging pharmaceutical technologies, and foster dialogue on regulatory challenges, ultimately facilitating innovation in drug development. Although it does not currently offer open access, its comprehensive and high-quality content remains essential for researchers, professionals, and students pursuing excellence in pharmaceutical research and patent analysis.

Metrics 2024

SCIMAGO Journal Rank0.35
Journal Impact Factor1.80
Journal Impact Factor (5 years)1.80
H-Index20
Journal IF Without Self1.80
Eigen Factor0.00
Normal Eigen Factor0.04
Influence0.34
Immediacy Index0.40
Cited Half Life7.00
Citing Half Life5.40
JCI0.29
Total Documents370
WOS Total Citations253
SCIMAGO Total Citations828
SCIMAGO SELF Citations23
Scopus Journal Rank0.35
Cites / Document (2 Years)1.18
Cites / Document (3 Years)1.15
Cites / Document (4 Years)1.01

Metrics History

Rank 2024

Scopus

Pharmaceutical Science in Pharmacology, Toxicology and Pharmaceutics
Rank #105/183
Percentile 42.62
Quartile Q3
Drug Discovery in Pharmacology, Toxicology and Pharmaceutics
Rank #122/157
Percentile 22.29
Quartile Q4

IF (Web Of Science)

PHARMACOLOGY & PHARMACY
Rank 240/354
Percentile 32.30
Quartile Q3

JCI (Web Of Science)

PHARMACOLOGY & PHARMACY
Rank 293/354
Percentile 17.23
Quartile Q4

Quartile History

Similar Journals

NATURE REVIEWS DRUG DISCOVERY

Shaping the future of therapeutic advancements.
Publisher: NATURE PORTFOLIOISSN: 1474-1776Frequency: 12 issues/year

Nature Reviews Drug Discovery, published by Nature Portfolio, is a premier academic journal dedicated to the field of drug discovery. Since its inception in 2002, this journal has become an essential resource for researchers, professionals, and students, providing high-quality, peer-reviewed articles that present the latest advancements and insights into the complex landscape of pharmaceutical development. With an impressive impact factor placing it in the Q1 category across multiple disciplines, including Drug Discovery and Pharmacology, it continues to lead the way in pharmacological research, evidenced by its top ranks in Scopus among peers. Although it is not an open-access publication, the journal remains a vital tool for those looking to stay abreast of emerging trends and innovations in drug research. For more details about their submission guidelines and access options, visit the official journal website.

Future Journal of Pharmaceutical Sciences

Fostering Knowledge Exchange in Pharmaceutical Sciences
Publisher: SPRINGERISSN: 2314-7245Frequency: 1 issue/year

The Future Journal of Pharmaceutical Sciences, published by Springer, stands as a vital resource in the realm of pharmaceutical research and innovation. Recognized for its open access initiative since 2015, this journal promotes extensive dissemination of cutting-edge discoveries, fostering collaboration among researchers, industry professionals, and students alike. With an ISSN of 2314-7245 and an E-ISSN of 2314-7253, it aims to bridge the gap between laboratory research and practical applications in the pharmaceutical sciences. Although specific metrics like HIndex and Scopus ranks are currently unavailable, the journal's commitment to high-quality, peer-reviewed content positions it as a promising platform for advancing pharmaceutical science. By engaging with this journal, contributors and readers can participate in the vibrant discourse shaping the future of drug development, therapeutic strategies, and healthcare solutions.

PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY

Innovative Insights for Enhanced Drug Formulation and Safety.
Publisher: TAYLOR & FRANCIS LTDISSN: 1083-7450Frequency: 6 issues/year

PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY is a premier journal published by Taylor & Francis Ltd that focuses on the latest advancements and innovations in the field of pharmaceutical science. Established in 1996, this journal has evolved to encompass a wide array of interdisciplinary studies relevant to drug development, formulation technology, and delivery systems, serving as a platform for researchers and professionals to share groundbreaking findings. With an impressive impact factor and ranked in both Q2 in Pharmaceutical Science and Q3 in Medicine (miscellaneous), it positions itself among the top-tier journals in pharmacology and toxicology. The journal's insights are critical for scholars and practitioners aiming to enhance therapeutic efficacy and safety. Access options for the content remain traditional, thus supporting a comprehensive approach to scientific literature. Throughout its converged years up to 2024, PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY continues to play a vital role in shaping pharmaceutical education and practice.

CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Unveiling Breakthroughs in Biotechnological Applications
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1389-2010Frequency: 15 issues/year

CURRENT PHARMACEUTICAL BIOTECHNOLOGY is a prestigious academic journal dedicated to advancing the field of pharmaceutical biotechnology by publishing high-quality research articles, reviews, and innovatory methodologies. Published by Bentham Science Publishers Ltd, this journal has established a strong reputation in its field, reflected in its 2023 Scopus rankings: it holds an impressive Q2 classification in Pharmaceutical Science and Q3 in Biotechnology, indicating its significant impact within these disciplines. With an ISSN of 1389-2010 and an E-ISSN of 1873-4316, CURRENT PHARMACEUTICAL BIOTECHNOLOGY provides a reliable platform for disseminating valuable research findings and fostering collaboration among researchers, professionals, and students alike. The journal covers a wide array of topics, from drug development and delivery systems to innovative biotechnological techniques, thus serving as an essential resource for anyone interested in the cross-section of pharmaceutical science and biotechnology. Researchers can access a diverse range of articles that explore both theoretical frameworks and practical applications, reflecting the ongoing evolution and challenges in this dynamic field.

Journal of Intellectual Property Law & Practice

Championing rigorous scholarship in IP practice.
Publisher: OXFORD UNIV PRESSISSN: 1747-1532Frequency: 12 issues/year

The Journal of Intellectual Property Law & Practice, published by Oxford University Press, is a premier academic journal dedicated to the exploration and discussion of issues surrounding intellectual property law. With an ISSN of 1747-1532 and an E-ISSN of 1747-1540, this journal has established itself as an essential resource in the field, featuring high-quality articles that contribute to the advancement of legal scholarship and practice. Recognized in the 2023 Category Quartiles as Q2 in Law, the journal ranks within the top half of its field and provides a global platform for researchers, practitioners, and policymakers. Covering a comprehensive range of topics from copyright to patent law, the journal encourages interdisciplinary dialogue and aims to bridge academic and professional practice. Although it operates under subscription models, it ensures wide accessibility of its rigorous content and analysis, maintaining its significance in shaping the discourse on intellectual property law from its inception in 2005 to the anticipated 2024. This journal not only supports scholarly communication but also fosters a community committed to the dynamic challenges of intellectual property in today’s innovative landscape.

International Journal of Pharmaceutics-X

Catalyzing collaboration in cutting-edge pharmaceutical research.
Publisher: ELSEVIERISSN: Frequency: 1 issue/year

International Journal of Pharmaceutics-X is a premier open access journal published by Elsevier, dedicated to advancing knowledge and research in the field of pharmaceutical sciences. Launched in 2019, this journal has quickly ascended to the Q1 category in the 2023 Category Quartiles, reflecting its high impact and the quality of research it promotes. With a current Scopus ranking of #49 out of 183 in the Pharmacology, Toxicology and Pharmaceutics category, this journal occupies the 73rd percentile, showcasing its significant influence within the scholarly community. Emphasizing innovative research and novel applications, the International Journal of Pharmaceutics-X offers a platform for researchers, professionals, and students to disseminate their findings, making crucial contributions to the global pharmaceutical landscape. The journal is based in the Netherlands, presenting a vibrant hub for scientific discourse and collaboration in a rapidly evolving field.

Journal of Reports in Pharmaceutical Sciences

Unveiling the Future of Biopharmaceutical Technologies.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 2322-1232Frequency: 2 issues/year

Journal of Reports in Pharmaceutical Sciences is a pivotal publication in the realm of pharmaceutical research, disseminating innovative findings that cater to the evolving landscape of pharmacology, toxicology, and biomedical engineering. Published by Wolters Kluwer Medknow Publications, the journal serves as a bridge for scholars and practitioners aiming to enhance their understanding of drug development, therapeutic advances, and biopharmaceutical technologies. With an ISSN of 2322-1232 and E-ISSN 2322-5106, it has established its relevance from 2012 to 2022, occupying notable quartile rankings, including Q3 in Pharmacology, Toxicology, and Pharmaceutics. Despite being categorized in Q4 in some areas, the journal's commitment to quality research ensures it remains a respected platform for disseminating significant insights. Researchers, professionals, and students alike will find this journal an indispensable resource for staying updated on critical advancements in pharmaceutical sciences, making it a go-to source for impactful studies that shape industry practices and academic inquiries.

Pharmaceuticals

Elevating Health Outcomes Through Cutting-Edge Discoveries
Publisher: MDPIISSN: Frequency: 12 issues/year

Ph pharmaceuticals is a leading peer-reviewed journal published by MDPI, focused on the dynamic fields of pharmaceutical science, drug discovery, and molecular medicine. Since its inception, the journal has established itself as a vital resource for researchers and practitioners, boasting an impressive impact factor reflected in its Q1 and Q2 quartile rankings across multiple categories, including Pharmaceutical Science and Drug Discovery. As an open access journal since 2009, Pharmaceuticals promotes the dissemination of cutting-edge research and innovative findings globally, facilitating collaboration and knowledge sharing among scientists. With a robust ranking in Scopus, specifically at Rank #56 in Pharmaceutical Science and Rank #65 in Drug Discovery, the journal serves as a critical platform for advancing the field and supporting future developments in therapeutics and pharmaceuticals. Based in Switzerland, Pharmaceuticals continues to inspire a diverse readership of scholars and healthcare professionals who are dedicated to improving health outcomes through innovative research.

MOLECULAR PHARMACEUTICS

Unraveling Molecular Mechanisms for Enhanced Drug Discovery
Publisher: AMER CHEMICAL SOCISSN: 1543-8384Frequency: 6 issues/year

MOLECULAR PHARMACEUTICS, published by the American Chemical Society, stands as a pivotal journal within the fields of Drug Discovery, Molecular Medicine, and Pharmaceutical Science, as evidenced by its impressive rankings in various categories, including Q1 in Drug Discovery and Pharmaceutical Science. With an ISSN of 1543-8384 and an E-ISSN of 1543-8392, this journal has been at the forefront of research since its inception in 2004 and continues to foster innovation and collaboration among researchers, professionals, and students well into 2024. The journal is noted for its significant impact, having achieved a Scopus ranking of #31 in Pharmaceutical Science and #36 in Drug Discovery, placing it in the top percentiles of the respective fields. While it currently does not offer Open Access, MOLECULAR PHARMACEUTICS remains an essential resource for advancing the understanding of molecular mechanisms in drug development and therapeutic strategies, ensuring that cutting-edge findings reach a wide audience and contribute to the progression of pharmaceutical sciences.

PHARMACEUTICAL RESEARCH

Advancing pharmaceutical innovation through rigorous research.
Publisher: SPRINGER/PLENUM PUBLISHERSISSN: 0724-8741Frequency: 12 issues/year

PHARMACEUTICAL RESEARCH, published by SPRINGER/PLENUM PUBLISHERS, is a leading journal in the ever-evolving field of pharmaceutical sciences. With an ISSN of 0724-8741 and an E-ISSN of 1573-904X, this journal has established itself as a critical hub for disseminating innovative research from 1984 to 2024. The journal holds impressive rankings in prominent categories, including Q2 in Biotechnology and Q2 in Pharmaceutical Science, reflecting its robust impact on the global scientific community. The journal aims to provide researchers, professionals, and students with high-quality articles that contribute significantly to the advancement of drug development and medicinal applications. Although it does not currently offer Open Access options, its rigorous peer-review process ensures that only the highest caliber research is published, making it a valuable resource for those seeking to stay at the forefront of pharmaceutical innovation.